Inhibition of HCV IRES controlled reporter gene expression by RNA interference.
- Author:
Wei-xian CHEN
1
;
Lin-na SHAN
;
Juan CHEN
;
Zhen-zhen ZHANG
;
Bing-qiang ZHANG
;
Ai-long HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Gene Expression Regulation; Genes, Reporter; Genetic Therapy; Genetic Vectors; Hep G2 Cells; Hepacivirus; genetics; Hepatitis C; therapy; Humans; RNA Interference; RNA, Messenger; genetics; Ribosomes; genetics; metabolism; Transfection
- From: Chinese Journal of Hepatology 2006;14(7):521-524
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo develop a RNAi approach that specifically targets the HCV IRES sequence by vector-expressed short hairpin RNA (shRNA) in vitro, and to assess the inhibitory effect of the shRNA on reporter gene expression.
METHODSEukaryotic expressing plasmids, pIRES-GFP and p5' UTR-Luc containing GFP or luciferase gene controlled by HCV IRES were cotransfected into HepG2 cells with either a RNAi plasmid pshRNA-HCV or a control plasmid pTZU6+1. At 24, 48, 72 hours post transfection, the fluorescence in the transfected cells was studied using fluorescence microscopy. The levels of GFP RNA were determined using RT-PCR and those of protein were determined using Western blot. The activities of luciferase were assayed using a dual luciferase assay system.
RESULTSThe introduction of RNAi plasmid efficiently and specifically down-regulated the expression of the reporter gene. RT-PCR showed that the RNAs of GFP gene were distinctly reduced (about 60%) when the pIRES-GFP was cotransfected with pshRNA-HCV, whereas the control vector did not exhibit inhibitory effect on the mRNA level, according to Western blot assay. The luciferase activity also decreased by 60%-70% in comparison to the control plasmid.
CONCLUSIONOur results demonstrate that the shRNA targeting HCV IRES shows a strong inhibitive effect on the expression of the reporter gene controlled by this sequence, suggesting that RNAi-based anti-HCV strategy may represent a potential approach in the therapy of HCV infection.